Cytek Biosciences, Inc. (CTKB) Misses Q3 EPS by 8c

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q3 EPS of ($0.05), $0.08 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $48 million versus the consensus estimate of $55.48 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c